Novel Targets is a podcast about the science and people involved in the development of innovative new drugs, gene and cell therapies. To date we’ve focused on cancer drug development and in particular some of the latest cancer immunotherapy research.
It reaches a broad global audience of “influencers” interested in the latest cancer research.
The show looks at some of the emerging new targets and approaches that could make a difference to the lives of patients. It discusses data from clinical trials and engages experts.
The aim is to inform, educate and create awareness. It occasionally entertains.
Follow the Podcast on Twitter: @TargetsPodcast
Sally Church, PhD
Sally is the executive producer of Novel Targets and ensures the scientific accuracy of the show’s output.
A member of the National Association of Science Writers (NASW) and Association of Health Care Journalists (AHCJ), Sally has over the last 10 years written over a thousand blog posts on cancer drug development on Pharma Strategy Blog; she now writes on Biotech Strategy Blog.
Follow Sally on Twitter: @MaverickNY
Genentech (@Genentech) are the lead sponsor for Novel Targets. They’ve renewed their sponsorship for 5 episodes in Season 4.
Each episode Genentech supports usually features a short vignette or mini-interview with one of their scientists that highlights their passion in “helping people combat the world’s hardest-to-treat diseases.”
The Loncar Cancer Immunotherapy Index sponsored Episode 14: Cell Therapy Pioneers.
It reached No 21 in the US iTunes/Apple Podcasts chart for Medicine related podcasts.
We’re grateful for all the sponsor support we’ve obtained without which the podcast would not have happened!
If we do mention any products or people from any sponsor (outside of the sponsorship mention), then it’s because they merit commentary or inclusion.
The podcast is editorially independent – we say what we want to say – sponsors have no control over content, who we interview, what topics we talk about or the questions we ask!